Peng et al. constructed a signature of T cell dysfunction and exclusion, and it was found that this signature was more accurate than PD-L1 expression and tumor mutation burden (TMB) in predicting the efficacy of immunotherapy in melanoma23. The gene discussed is CD274; the disease is neoplasm.